Magnetic Steering and Longitudinal Visualization of Stem Cells for Trabecular Meshwork Therapy in Glaucoma

用于青光眼小梁网治疗的干细胞磁控和纵向可视化

• 批准号: 10459456
• 负责人: STANISLAV Y EMELIANOV
• 金额: $ 49.82万
• 依托单位: GEORGIA INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10459456
• 关键词: Abbreviations; Anterior; Apoptosis; Area; Blindness; CASP3 gene; Cell Culture Techniques; Cell Survival; Cells; Cellularity; Data; Disease; Dyes; Effectiveness; Eye; Eye diseases; Family suidae; Glaucoma; Glossary; Goals; Histologic; Homeostasis; Human; Hydrogen Peroxide; Image; In Situ; Inflammatory; Label; Location; Magnetic nanoparticles; Magnetism; Mesenchymal Stem Cells; Modeling; Monitor; Mus; Mutate; Nanotechnology; Ocular Hypertension; Organ Culture Techniques; Patients; Peptides; Photosensitivity; Physiologic Intraocular Pressure; Primary Open Angle Glaucoma; Property; RNA; Reporter; Research; Risk; Risk Factors; Spatial Distribution; Specificity; System; Technology; Testing; Time; Tissues; Trabecular meshwork structure; Transgenic Mice; Vesicle; Visualization; Work; anterior chamber; cellular imaging; comparative efficacy; cytokine; delivery vehicle; design; experimental study; imaging platform; imaging system; improved; in vivo; induced pluripotent stem cell; innovation; instrument; interest; myocilin; nanoparticle; novel; outcome prediction; photoacoustic imaging; pressure; serial imaging; stem cell delivery; stem cell technology; stem cell therapy; stem cells; superparamagnetism; ultrasound; virtual

Project Summary/Abstract Glaucoma is a major cause of blindness and current treatments are insufficient. A major risk factor for glaucoma, and the only treatable risk factor, is elevated intraocular pressure (IOP). Current IOP-lowering therapies fail too often, and thus there continues to be great interest in novel IOP control strategies. The trabecular meshwork (TM), the key tissue determining IOP, has reduced cellularity in glaucoma, which has led a number of groups to study stem cell-based therapies for the TM. An obstacle to such therapies is cell delivery: current approaches have low cell delivery efficiency and specificity for the TM, and cannot deliver cells to all parts of the TM. Here a novel technological solution for “steering” stem cells to the TM is proposed, which can be additionally used to visualize stem cell delivery and to monitor stem cell apoptosis. This approach will be tested in several models of ocular hypertension. The key technology is superparamagnetic and photosensitive nanoparticles. Their superparamagnetic properties mean that cells which have taken up these nanoparticles can be rapidly steered to the TM by a magnet placed at the limbus. Their photosensitivity means that cells can be visualized by ultrasound/photoacoustic imaging in the living eye. The functionality of these nanoparticles will be further enhanced by using a photosensitive marker of active caspase-3 to monitor stem cell apoptosis. Our overall objective is to validate these technologies as a safe and effective approach for monitoring and steering of stem cells to the TM, thereby restoring intraocular pressure (IOP) homeostasis in glaucoma patients. Three specific aims towards this long-term goal are proposed, building on our significant preliminary data. In aim 1, a novel caspase-3-sensitive reporter for monitoring apoptosis will be synthesized and characterized, and magnets for steering stem cells to the TM will be optimized. In aim 2, an instrument capable of imaging of labeled stem cells in whole eyes, including longitudinal monitoring of stem cell distribution and apoptosis, will be developed. In aim 3, stem cells will be delivered to the TM in two glaucoma models, and their ability to restore IOP homeostasis will be evaluated. The ability of ultrasound/photoacoustic imaging to monitor stem cell delivery to the TM and stem cell apoptosis will also be validated; and mesenchymal stem cells (MSCs) will be compared to differentiated induced pluripotent stem cells (iPSC-TMs) for their efficacy in restoring IOP homeostasis. This project is highly innovative: it the first study to steer and visualize stem cells as part of a treatment for ocular hypertension. It is also the first to compare the efficacy of MSCs vs. iPSC-TMs for treating ocular hypertension. We expect, as suggested by our strong preliminary data, to discover that stem cells can be efficiently and selectively steered to the TM by a simple magnet placed at the limbus for as little as 15 minutes; and that it will be possible to accurately monitor the location of stem cells in the eye and stem cell apoptosis over time. Further, we expect that TM function will be improved by stem cells steered in this way, as tested in 2 glaucoma models.